423 related articles for article (PubMed ID: 19597425)
1. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.
Abou-Mourad YR; Lau BC; Barnett MJ; Forrest DL; Hogge DE; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Lavoie JC
Bone Marrow Transplant; 2010 Feb; 45(2):295-302. PubMed ID: 19597425
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
5. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
7. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
8. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J
Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043
[TBL] [Abstract][Full Text] [Related]
9. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
10. [Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies].
Wang F; Huang X; Ren H; Zhang Y; Xu L; Chen Y; Liu K; Guo N; Lu D
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):403-6. PubMed ID: 12411042
[TBL] [Abstract][Full Text] [Related]
11. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
12. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
13. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties.
Uderzo C; Pillon M; Corti P; Tridello G; Tana F; Zintl F; Nysom K; Galambrun C; Fagioli F; Varotto S; Messina C; Verdeguer A; Urban C; Faraci M; Dini G; Fedeli S; Tichelli A; Rovelli A; Socié G
Bone Marrow Transplant; 2007 Jun; 39(11):667-75. PubMed ID: 17401396
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic hematopoietic stem cell transplantation for acute lymphocytic leukemia].
Chen H; Ren HY; Guo NL; Huang XJ; Liu KY; Xu LP; Zhang YC; Zheng H; Wu T; Liu DH; Yang SM; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):87-90. PubMed ID: 14990046
[TBL] [Abstract][Full Text] [Related]
16. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
[TBL] [Abstract][Full Text] [Related]
20. [Liver biopsy in the management of liver dysfunction after allogeneic hematopoietic stem-cell transplantation].
Chen H; Huang XJ; Liu KY; Xu LP; Wang H; Liu DH; Lu J; Lu DP
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3062-6. PubMed ID: 16324408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
